Aspirin and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Aspirin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both apixaban (Eliquis) and aspirin make it harder for your blood to clot. Apixaban blocks a clotting protein, and aspirin makes your platelets less sticky. Taken together, they work on clotting in two different ways, so the effect adds up and your bleeding risk goes up. In some cases that bleeding can be serious.
This doesn't mean the combination is always wrong, since some people truly need both. The important thing is to watch for signs of bleeding, like unusual bruising, pink or red urine, black stools, nosebleeds that won't stop, or coughing up blood. Report these right away or go to the ER. Your care team can manage this safely, so please don't stop either drug on your own.
Effect: Additive pharmacodynamic effect on hemostasis. Apixaban (direct factor Xa inhibitor) plus aspirin (irreversible COX-1/platelet inhibitor) increases bleeding risk, including serious or fatal bleeding. Neither drug is a prodrug in a way that alters this; the effect is purely additive PD, not PK.
- Direction: Increased combined antihemostatic effect.
- Evidence: Probable; onset unspecified.
- Management: Advise on bleeding signs/symptoms; promptly evaluate any blood loss. Discontinue apixaban with active pathological hemorrhage (PD effect persists ~24 h post-dose). In DVT/PE with stable CV disease, suspending aspirin during anticoagulation is suggested (conditional, very low certainty), but NOT for recent ACS or coronary intervention.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Using apixaban together with antiplatelet drugs like aspirin raises the likelihood of bleeding. In patients who develop active pathological hemorrhage, apixaban should be stopped. Patients should be informed about the signs and symptoms of blood loss and instructed to report them without delay or to present to an emergency room. Apixaban should be discontinued in patients experiencing active pathological hemorrhage. The pharmacodynamic activity of apixaban is anticipated to remain for a minimum of 24 hours following the final dose3. Any signs or symptoms of blood loss appearing in a patient receiving both anticoagulants and antiplatelet agents concurrently should be assessed promptly 4. For patients who have DVT and/or pulmonary embolism (PE) along with stable cardiovascular disease and who are taking aspirin to modify cardiovascular risk, it is suggested that aspirin be held throughout the period of anticoagulation therapy for DVT and/or PE (a conditional recommendation grounded in very low certainty in the evidence of effects); this suggestion, however, does not extend to patients who have had a recent acute coronary event or coronary intervention 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Many people are placed on this combination intentionally, and your care team will individualize the plan for you.
- Learn the warning signs of bleeding: unusual bruising, red or black stools, pink/red urine, prolonged nosebleeds, coughing or vomiting blood, or severe headache. Report these immediately or go to an ER.
- Ask your pharmacist or doctor whether you still need both. For some people with a blood clot (DVT/PE) and stable heart disease, the team may reconsider the aspirin, but this does not apply after a recent heart attack or stent.
- Remember apixaban's blood-thinning effect lasts at least 24 hours after the last dose.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients following acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel (APPRAISE-2) was stopped ahead of schedule because apixaban produced more bleeding than placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban compared with 0.6% per year with placebo, and among those on dual antiplatelet therapy it was 5.9% per year with apixaban compared with 2.5% per year with placebo 3.
b) In a clinical trial (ARISTOTLE), among patients taking apixaban, adding aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, and adding both aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year; use of dual antiplatelet therapy along with apixaban was limited (2.3%) in this trial 3.
c) In a retrospective study, combining direct oral anticoagulant (DOAC) therapy with antiplatelet therapy (APT; n=78) versus DOAC therapy by itself (n=329) did not meaningfully change the rate of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mostly Caucasian men with a mean age of 63.7 years. Those on concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), higher mean CHA2DS2-VASc score (4.28 vs 3.85), and were more often diabetic (26.9% vs 17.3%) than those given DOAC monotherapy. DOACs were prescribed for VTE treatment or atrial fibrillation and comprised apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most frequent regimen (69 patients). Additional APT regimens included aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 2.
Common questions
Can I take Aspirin and Apixaban together?
Combining Eliquis and aspirin adds up to a higher, sometimes serious, bleeding risk, so watch closely for any signs of bleeding and report them right away. Don't stop either drug on your own; let your care team decide whether you need both. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Aspirin and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Aspirin and Apixaban interaction managed?
Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Many people are placed on this combination intentionally, and your care team will individualize the plan for you. Learn the warning signs of bleeding: unusual bruising, red or black stools, pink/red urine, prolonged nosebleeds, coughing or vomiting blood, or severe headache. Report these immediately or go to an ER.… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
- Can You Take Baobab Fiber With Eliquis (Apixaban)?
- Can You Replace an Evening Apixaban Dose With Berberine?
- Can I Take Ginkgo With Apixaban (Eliquis) and Atorvastatin?
- Is Hibiscus Tea Safe With Metoprolol, Losartan, and Aspirin?
- Is It Risky to Take Low Dose Aspirin With Nattokinase?
- Acetaminophen, Aspirin And Ibuprofen Considerations Before Surgery
Questions for your pharmacist
- Does my dose of Aspirin or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Ortel TL, Neumann I, Ageno W, et al: American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4(19):4693-4738. DOI
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
Keep reading about Apixaban
Keep reading about Aspirin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist